Stryker, a global leader in medical technologies, has completed the acquisition of MOLLI Surgical Inc., a privately held company specializing in the development of wire-free soft tissue localization technology for breast conserving surgery. MOLLI’s portfolio further strengthens Stryker’s commitment to advancing surgical solutions in breast cancer care.
The MOLLI 2 localization system is designed for ease of use and reliability to support a more efficient surgical workflow. The MOLLI Marker is the smallest on the market at 3.2 mm and is detectable in dense breasts and through hematoma. The MOLLI 2 tablet provides surgeons with four real-time types of feedback: distance, visual, auditory and 3D directional guidance.
Stikeman Elliott acted as legal counsel to Stryker with a team that included Michael Decicco, Christopher Sullivan, Alexandra Mathieu (M&A), John Lennard, Rebekah Dong (Tax), Sara Zborovski, Ian Trimble (Regulatory), Kathleen Chevalier, Khalfan Khalfan, Danielle Jager, Juliette Bousquet (Employment), Natasha vandenHoven, Sagar Darar (Pensions and Benefits), Jeilah Chan (Intellectual Property), Spencer Abraham (Real Estate)
